Bristol-Myers Squibb unit completes €5.0 billion euro bond sale in five tranches
On November 10, 2025, BMS Ireland Capital Funding Designated Activity Company, a wholly owned subsidiary, completed a public offering of five series of euro-denominated senior unsecured notes guaranteed by Bristol-Myers Squibb. The company plans to use the proceeds, together with approximately $3.0 billion of cash on hand, mainly to fund a tender offer for various series of its outstanding notes, with any remaining proceeds for general corporate purposes. For shareholders, the filing shows a debt refinancing that reshapes the maturity profile rather than a change in operations.
Key points
- Five series totaling €5.0 billion: €750 million due 2030, €1.15 billion due 2033, €1.15 billion due 2038, €750 million due 2045, and €1.2 billion due 2055
- Coupons range from 2.973% (2030 Notes) to 4.581% (2055 Notes), with interest payable annually beginning November 10, 2026
- Proceeds, plus about $3.0 billion of cash on hand, are earmarked for the tender offer for outstanding notes, fees and expenses, and general corporate purposes
- Offering made under a prospectus supplement dated November 5, 2025 and an underwriting agreement dated November 5, 2025
The filing
Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 10, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.